Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease

Observational studies suggest that single-tablet formulations are associated with improved adherence versus the same components taken as separate tablets. The objective of this study was to compare adherence in patients with Parkinson's disease (PD) receiving levodopa therapy as levodopa/carbid...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2010-07, Vol.26 (7), p.1543-1552
Main Authors: Delea, Thomas E., Thomas, Simu K., Hagiwara, May, Mancione, L.
Format: Article
Language:English
Subjects:
Adherence
Aged
Aged, 80 and over
Algorithms
Antiparkinson Agents - administration & dosage
Antiparkinson Agents - adverse effects
Carbidopa - administration & dosage
Carbidopa - adverse effects
Catechols - administration & dosage
Catechols - adverse effects
Cohort Studies
Dosage Forms
Drug Combinations
Female
Humans
Levodopa - administration & dosage
Levodopa - adverse effects
Male
Middle Aged
Motor complications
Nitriles - administration & dosage
Nitriles - adverse effects
Parkinson Disease - drug therapy
Parkinson Disease - epidemiology
Parkinson's disease
Patient Compliance - statistics & numerical data
Retrospective Studies
Tablets
Wearing-off
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Observational studies suggest that single-tablet formulations are associated with improved adherence versus the same components taken as separate tablets. The objective of this study was to compare adherence in patients with Parkinson's disease (PD) receiving levodopa therapy as levodopa/carbidopa/entacapone tablets (LCE) versus levodopa/carbidopa (LC) tablets and entacapone (E) as separate tablets (LC and E). This was a retrospective, observational cohort study using a large health insurance claims database. Subjects included persons with a PD diagnosis who were receiving LC without E and then received either an add-on therapy with E as a separate tablet (LC and E) or LCE as one tablet (LCE). The primary study outcome was treatment adherence, estimated from pharmacy refills based on the 'percent of days covered' (PDC) with LCE or LC and E during follow-up and compared for patients receiving LCE and LC and E using multivariate regression analyses. In multivariate analyses controlling for differences between groups in baseline characteristics, including pre-index dosage of and adherence with LC, receipt of LCE (n = 388) was associated with 79% lower mean non-adherence during follow-up (95% CI: 73-83%; p 
ISSN:0300-7995
1473-4877
DOI:10.1185/03007991003780628